scPharmaceuticals Inc
SCPH5.670USD
0.0000.00%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
302.16MMarket Cap
LossP/E TTM
More Details of scPharmaceuticals Inc Company
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company develops, internally and through strategic partnerships, products and solutions that aim to expand and advance the outpatient care of select acute conditions. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Companay’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
scPharmaceuticals Inc Info
Ticker SymbolSCPH
Company namescPharmaceuticals Inc
IPO dateNov 17, 2017
CEOMr. John H. Tucker
Number of employees162
Security typeOrdinary Share
Fiscal year-endNov 17
Address25 Burlington Mall Road, Suite 203
CityBURLINGTON
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code01803
Phone16175170730
Websitehttps://www.scpharmaceuticals.com/
Ticker SymbolSCPH
IPO dateNov 17, 2017
CEOMr. John H. Tucker
Company Executives of scPharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Miranda
Ms. Katherine Miranda
Senior Manager - Corporate Communication
Senior Manager - Corporate Communication
--
--
Mr. Michael E. Castagna
Mr. Michael E. Castagna
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Chris Prentiss
Mr. Chris Prentiss
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. David Thomson
Mr. David Thomson
Company Secretary, Director
Company Secretary, Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Fri, Feb 6
Updated: Fri, Feb 6
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
9.50%
Weiss Asset Management
5.37%
Lundbeckfond Invest
5.34%
BlackRock Institutional Trust Company, N.A.
4.02%
Other
64.48%
Shareholders
Shareholders
Proportion
OrbiMed Advisors, LLC
11.29%
Rubric Capital Management LP
9.50%
Weiss Asset Management
5.37%
Lundbeckfond Invest
5.34%
BlackRock Institutional Trust Company, N.A.
4.02%
Other
64.48%
Shareholder Types
Shareholders
Proportion
Hedge Fund
27.92%
Investment Advisor
17.99%
Private Equity
12.37%
Investment Advisor/Hedge Fund
10.10%
Research Firm
4.68%
Individual Investor
0.36%
Venture Capital
0.12%
Bank and Trust
0.07%
Pension Fund
0.03%
Other
26.35%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
224
41.16M
76.68%
-3.36M
2025Q3
203
37.70M
70.24%
-12.04M
2025Q2
207
43.86M
83.06%
-9.87M
2025Q1
220
46.17M
87.73%
-9.39M
2024Q4
216
48.09M
96.18%
-7.84M
2024Q3
205
45.54M
91.15%
-1.25M
2024Q2
187
32.09M
87.10%
-11.64M
2024Q1
180
29.20M
80.96%
-13.79M
2023Q4
174
29.67M
82.49%
-9.34M
2023Q3
165
32.24M
89.90%
-5.09M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
OrbiMed Advisors, LLC
6.06M
11.29%
--
--
Sep 30, 2025
Rubric Capital Management LP
5.10M
9.5%
+499.91K
+10.86%
Sep 30, 2025
Weiss Asset Management
2.88M
5.37%
+2.88M
--
Sep 30, 2025
Lundbeckfond Invest
2.86M
5.34%
+2.86M
--
Sep 30, 2024
BlackRock Institutional Trust Company, N.A.
2.16M
4.02%
+168.78K
+8.49%
Sep 30, 2025
Tudor Investment Corporation
2.15M
4.01%
+2.15M
--
Sep 30, 2025
Luther King Capital Management Corp.
2.13M
3.96%
-1.41M
-39.90%
Sep 30, 2025
HSBC Global Asset Management (UK) Limited
1.90M
3.54%
+1.90M
--
Sep 30, 2025
Morgan Stanley & Co. LLC
1.59M
2.95%
-76.49K
-4.60%
Sep 30, 2025
Glazer Capital, LLC
1.38M
2.57%
+1.38M
--
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 3000 ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Proshares Ultra Russell 2000
0%
ProShares Ultra Nasdaq Biotechnology
0%
iShares Russell 2000 Growth ETF
0%
Invesco Nasdaq Biotechnology ETF
0%
View more
Global X Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Invesco NASDAQ Future Gen 200 ETF
Proportion0%
iShares Russell 3000 ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
iShares Micro-Cap ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares Ultra Nasdaq Biotechnology
Proportion0%
iShares Russell 2000 Growth ETF
Proportion0%
Invesco Nasdaq Biotechnology ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
